主要股东出售了1.1M Werewolf治疗股份,减少了股本,因为公司的损失比预期的要小。 Major shareholders sold 1.1M Werewolf Therapeutics shares, reducing stakes, as company posted a smaller-than-expected loss.

大型狼人治疗股东Bioventures 2014 L.P. Mpm和安斯伯特·加迪克在2025年11月11日至25日期间以0.83美元至1.14美元的价格出售了总共110万股股票,产生了超过98万美元的收益. Major Werewolf Therapeutics shareholders Bioventures 2014 L.P. Mpm and Ansbert Gadicke sold a combined 1.1 million shares between November 11 and 25, 2025, at prices between $0.83 and $1.14, generating over $980,000. 由于Gadicke持有的股份下降到5 125 770股,销售量大大减少了他们的股权。 The sales reduced their stakes significantly, with Gadicke's holding dropping to 5,125,770 shares. 该公司报告季度损失每股0.36美元,略高于预期,于11月25日以91美元关闭,市场上限为4 419万美元。 The company reported a quarterly loss of $0.36 per share, slightly better than expected, and closed at $0.91 on November 25 with a market cap of $44.19 million. 分析师持有不同意见,具有协商一致的“机动购买”评级和7.75美元目标价格。 Analysts hold mixed views, with a consensus "Moderate Buy" rating and a $7.75 target price.